Volume 13, Issue 1 (Winter 2024)
aumj 2024, 13(1): 9-16 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghaie T, Gorgani M, Motallebnezhad M, Jazayeri M H. Comparison of the PD-1 expression level in peripheral blood of Multiple Sclerosis and Neuromyelitis Optica patients. aumj 2024; 13 (1) :9-16
URL: http://aums.abzums.ac.ir/article-1-1666-en.html
URL: http://aums.abzums.ac.ir/article-1-1666-en.html
1- Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.Immunology Research Center, Institute of Immunology and Infectious Disease, Iran University of Medical Sciences, Tehran, Iran.
Abstract: (762 Views)
Programmed cell death-1 (PD-1) is one of the important co-inhibitory receptors in maintaining tolerance and inhibiting the proliferation and activity of activated immune cells. PD-1: PD-L pathway enhances regulatory T cells proliferation and inhibition of autoreactive T cells and regulates central and peripheral tolerance. This pathway has affected various aspects of the immune system and is of particular importance in a variety of diseases, such as autoimmune diseases. Multiple sclerosis (MS) and Neuromyelitis Optica (NMO) are neurological disorders characterized by inflammation, demyelination by the immune system, and axonal and neuronal damage in the CNS. The clinical manifestations of NMO are very similar to MS and lead to a misdiagnosis. Therefore, the existence of specific diagnostic markers is of particular importance for correct diagnosis. Here, we examined the expression of the PD-1 gene in 40 MS patients, 20 NMO patients, and 15 healthy individuals. Thus, after RNA extraction from human blood and cDNA synthesis, gene expression of PD-1 was investigated using quantitative real-time PCR technique. The results show that the PD-1 mRNA expression in the peripheral blood of the MS group was significantly increased in comparison to that of the NMO group and healthy group (p= 0.0008, p= 0.0024, respectively). However, there was no significant difference in PD-1 mRNA expression between the NMO group and the healthy group.
Keywords: Multiple sclerosis, Neuromyelitis Optica, Misdiagnosis, PD-1, PD-L, T cell, Gene expression
Type of Study: Original |
Subject:
Special
Received: 2023/03/01 | Accepted: 2023/07/18 | Published: 2024/02/29
Received: 2023/03/01 | Accepted: 2023/07/18 | Published: 2024/02/29
References
1. Francisco LM, Sage PT, Sharpe AH. The PD‐1 pathway in tolerance and autoimmunity. Immunological reviews. 2010;236(1):219-42. [DOI:10.1111/j.1600-065X.2010.00923.x]
2. Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2 pathway from discovery to clinical implementation. Frontiers in immunology. 2016;7:550. [DOI:10.3389/fimmu.2016.00550]
3. Chitnis T, Khoury SJ. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of allergy and clinical immunology. 2003;112(5):837-49. [DOI:10.1016/j.jaci.2003.08.025]
4. Pittet CL, Newcombe J, Antel JP, Arbour N. The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD‐L1 levels on CNS cells. Glia. 2011;59(5):841-56. [DOI:10.1002/glia.21158]
5. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Current opinion in immunology. 2007;19(3):309-14. [DOI:10.1016/j.coi.2007.04.012]
6. Dinesh RK, Hahn BH, Singh RP. PD-1, gender, and autoimmunity. Autoimmunity reviews. 2010;9(8):583-7. [DOI:10.1016/j.autrev.2010.04.003]
7. Kroner A, Mehling M, Hemmer B, Rieckmann P, Toyka KV, Mäurer M, et al. A PD‐1 polymorphism is associated with disease progression in multiple sclerosis. Annals of neurology. 2005;58(1):50-7. [DOI:10.1002/ana.20514]
8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. International immunology. 2007;19(7):813-24. [DOI:10.1093/intimm/dxm057]
9. Carter LL, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD‐1: PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2. European journal of immunology. 2002;32(3):634-43.
https://doi.org/10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9 [DOI:10.1002/1521-4141(200203)32:33.0.CO;2-9]
10. Pittet CL, Newcombe J, Prat A, Arbour N. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. Journal of neuroinflammation. 2011;8(1):155. [DOI:10.1186/1742-2094-8-155]
11. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses. European journal of immunology. 2003;33(10):2706-16. [DOI:10.1002/eji.200324228]
12. Pawlak-Adamska E, Nowak O, Karabon L, Pokryszko-Dragan A, Partyka A, Tomkiewicz A, et al. PD-1 gene polymorphic variation is linked with first symptom of disease and severity of relapsing-remitting form of MS. Journal of neuroimmunology. 2017;305:115-27. [DOI:10.1016/j.jneuroim.2017.02.006]
13. Kroner A, Schwab N, Ip CW, Ortler S, Göbel K, Nave K-A, et al. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. The American journal of pathology. 2009;174(6):2290-9. [DOI:10.2353/ajpath.2009.081012]
14. Javan MR, Aslani S, Zamani MR, Rostamnejad J, Asadi M, Farhoodi M, et al. Downregulation of immunosuppressive molecules, PD-1 and PD-L1 but not PD-L2, in the patients with multiple sclerosis. Iranian Journal of Allergy, Asthma and Immunology. 2016;15(4):296-302.
15. Jazayeri MH, Barzaman K, Nedaeinia R, Aghaie T, Motallebnezhad M. Human placental extract attenuates neurological symptoms in the experimental autoimmune encephalomyelitis model of multiple sclerosis-a putative approach in MS disease? Auto Immun Highlights. 2020;11(1):14. [DOI:10.1186/s13317-020-00137-x]
16. Aghaie T, Jazayeri MH, Avan A, Anissian A, Salari AA. Gold nanoparticles and polyethylene glycol alleviate clinical symptoms and alter cytokine secretion in a mouse model of experimental autoimmune encephalomyelitis. IUBMB Life. 2019;71(9):1313-21. [DOI:10.1002/iub.2045]
17. Aghaie T, Jazayeri MH, Manian M, Khani L, Erfani M, Rezayi M, et al. Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases. J Cell Biochem. 2019;120(3):2749-55. [DOI:10.1002/jcb.27415]
18. Cencioni MT. The immune regulation of PD-1/PDL-1 axis, a potential biomarker in multiple sclerosis. Neuroimmunology and Neuroinflammation. 2020;7(3):277-90 [DOI:10.20517/2347-8659.2020.18]
19. Saheki T, Imachi H, Ibata T, Fukunaga K, Yoshioka Y, Kobayashi T, et al. A Case of Co-existing of Neuromyelitis Optica and Fulminant Type 1 Diabetes. Internal Medicine. 2019:2353-18. [DOI:10.2169/internalmedicine.2353-18]
20. Asgari N, Nielsen C, Stenager E, Kyvik KO, Lillevang ST. HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Multiple Sclerosis Journal. 2012;18(1):23-30. [DOI:10.1177/1352458511417480]
21. Asgari N. Epidemiological, clinical and immunological aspects of neuromyelitis optica (NMO). Dan Med J. 2013;60(10):B4730.
22. Gontika MP, Anagnostouli MC. Human leukocyte antigens‑immunogenetics of neuromyelitis optica or Devic's disease and the impact on the immunopathogenesis, diagnosis and treatment: a critical review. Neuroimmunology and Neuroinflammation. 2014;1(2):44. [DOI:10.4103/2347-8659.139713]
23. Alonso VR, de Jesus Flores Rivera J, Garci YR, Granados J, Sánchez T, Mena-Hernández L, et al. Neuromyelitis optica (NMO IgG+) and genetic susceptibility, potential ethnic influences. Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents). 2018;18(1):4-7. [DOI:10.2174/1871524916666160229115047]
24. Juryńczyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry. 2015;86(1):20-5. [DOI:10.1136/jnnp-2014-308984]
25. Fan X, Jiang Y, Han J, Liu J, Wei Y, Jiang X, et al. Circulating memory T follicular helper cells in patients with neuromyelitis optica/neuromyelitis optica spectrum disorders. Mediators of inflammation. 2016;2016. [DOI:10.1155/2016/3678152]
26. Kim H, Lee Y, Kim YH, Lim YM, Lee JS, Woo J, et al. Deep Learning-Based Method to Differentiate Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Front Neurol. 2020;11:599042. [DOI:10.3389/fneur.2020.599042]
27. Khimani K, Patel SP, Whyte A, Al-Zubidi N. Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. Front Oncol. 2022;12:806501. [DOI:10.3389/fonc.2022.806501]
28. Jazayeri MH, Barzaman K, Nedaeinia R, Aghaie T, Motallebnezhad M. Human placental extract attenuates neurological symptoms in the experimental autoimmune encephalomyelitis model of multiple sclerosis-a putative approach in MS disease? Auto Immun Highlights. 2020;11(1):14. [DOI:10.1186/s13317-020-00137-x]
29. Ibañez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos PI, Naves R. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. Journal of Autoimmunity. 2021;123:102702. [DOI:10.1016/j.jaut.2021.102702]
30. Machcińska M, Kierasińska M, Michniowska M, Maruszewska-Cheruiyot M, Szewczak L, Rola R, et al. Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS. International journal of molecular sciences. 2022;23(6):3185. [DOI:10.3390/ijms23063185]
31. Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: AT Cell Perspective. Frontiers in Cellular Neuroscience. 2021:267. [DOI:10.3389/fncel.2021.716747]
32. Xue Q, Li X, Gu Y, Wang X, Wang M, Tian J, et al. Unbalanced Expression of ICOS and PD-1 in Patients with Neuromyelitis Optica Spectrum Disorder. Scientific Reports. 2019;9(1):14130. [DOI:10.1038/s41598-019-50479-4]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
